Is there a future for antiviral fusion inhibitors?

被引:64
作者
Berkhout, Ben [1 ]
Eggink, Dirk [1 ,3 ]
Sanders, Rogier W. [1 ,2 ]
机构
[1] Univ Amsterdam, Lab Expt Virol, Dept Med Microbiol, Ctr Infect & Immun Amsterdam CINIMA,Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands
[2] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
[3] Mt Sinai Sch Med, Dept Microbiol, New York, NY USA
基金
欧洲研究理事会;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; 6-HELIX BUNDLE FORMATION; TYPE-1 ENTRY INHIBITORS; HIV-FUSION; PEPTIDE INHIBITOR; HEPTAD REPEAT; COILED-COIL; CCR5; ANTAGONIST; MEMBRANE-FUSION; MULTIFUNCTIONAL DOMAINS;
D O I
10.1016/j.coviro.2012.01.002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by attachment of the envelope glycoproteins, gp120 and gp41, to the CD4 receptor and a chemokine receptor (CCR5 or CXCR4) and subsequent fusion of viral and cellular membranes. Several steps of the entry process can be targeted by drugs. Receptor antagonists prevent virus attachment and fusion inhibitors block conformational changes that are required for membrane fusion. The T20 peptide (Enfuvirtide, Fuzeon), which is homologous to part of the gp41-encoded fusion machinery, is the only clinically approved fusion inhibitor, but over the last decade new generations of T20-like peptides have been developed with improved potency and stability, as well as fusion inhibitors that target alternative gp41 domains. Here, we will review the field of HIV-1 fusion inhibitors.
引用
收藏
页码:50 / 59
页数:10
相关论文
共 119 条
  • [1] EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES
    ALLAWAY, GP
    DAVISBRUNO, KL
    BEAUDRY, GA
    GARCIA, EB
    WONG, EL
    RYDER, AM
    HASEL, KW
    GAUDUIN, MC
    KOUP, RA
    MCDOUGAL, JS
    MADDON, PJ
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (05) : 533 - 539
  • [2] HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
    Armand-Ugón, M
    Gutiérrez, A
    Clotet, B
    Esté, JA
    [J]. ANTIVIRAL RESEARCH, 2003, 59 (02) : 137 - 142
  • [3] Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor
    Baldwin, CE
    Sanders, RW
    Deng, YQ
    Jurriaans, S
    Lange, JM
    Lu, M
    Berkhout, B
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (22) : 12428 - 12437
  • [4] Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant
    Baldwin, Chris
    Berkhout, Ben
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (15) : 7735 - 7740
  • [5] Berkhout B, 1999, J BIOMED SCI, V6, P298, DOI 10.1159/000025401
  • [6] Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41
    Bewley, CA
    Louis, JM
    Ghirlando, R
    Clore, GM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (16) : 14238 - 14245
  • [7] Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection
    Bianchi, E
    Finotto, M
    Ingallinella, P
    Hrin, R
    Carella, AV
    Hou, XS
    Schleif, WA
    Miller, MD
    Geleziunas, R
    Pessi, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (36) : 12903 - 12908
  • [8] Bjorndal A, 1997, J VIROL, V71, P7478
  • [9] Severe acute respiratory syndrome coroavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides
    Bosch, BJ
    Martina, BEE
    van der Zee, R
    Lepault, J
    Haijema, BJ
    Versluis, C
    Heck, AJR
    de Groot, R
    Osterhaus, ADME
    Rottier, PJM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (22) : 8455 - 8460
  • [10] STRUCTURE OF INFLUENZA HEMAGGLUTININ AT THE PH OF MEMBRANE-FUSION
    BULLOUGH, PA
    HUGHSON, FM
    SKEHEL, JJ
    WILEY, DC
    [J]. NATURE, 1994, 371 (6492) : 37 - 43